AMRX (Amneal Pharmaceuticals) Accounts Payable: $228 Mil (As of Mar. 2026)


AMRX Amneal Pharmaceuticals Inc AMRX
63 GF Score
Price $17.16
GF Value $7.58
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals Accounts Payable?

Amneal Pharmaceuticals AMRX +1.00% 63 Accounts Payable is $228 Mil as of Mar. 2026. GuruFocus rates AMRX with a GF Score™ of 63/100 and a GF Value™ of $7.58 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Amneal Pharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2026 was $228 Mil.

Amneal Pharmaceuticals's quarterly Accounts Payable declined from Sep. 2025 ($266 Mil) to Dec. 2025 ($255 Mil) and declined from Dec. 2025 ($255 Mil) to Mar. 2026 ($228 Mil).

Amneal Pharmaceuticals's annual Accounts Payable increased from Dec. 2023 ($144 Mil) to Dec. 2024 ($259 Mil) but then declined from Dec. 2024 ($259 Mil) to Dec. 2025 ($255 Mil).

Amneal Pharmaceuticals Accounts Payable Related Terms

Amneal Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals Accounts Payable Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 131.08 165.98 143.57 258.69 254.67

Amneal Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 192.53 205.81 266.36 254.67 227.68
AMRX
63GF Score
Amneal Pharmaceuticals Inc AMRX
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amneal Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $228 Mil mean?
Amneal Pharmaceuticals (AMRX) has a Accounts Payable of $228 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Amneal Pharmaceuticals and its competitors.
Is Amneal Pharmaceuticals' Accounts Payable too high?
Amneal Pharmaceuticals' current Accounts Payable is $228 Mil. Overall, Amneal Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Accounts Payable compare to INDV and KNSA?
Amneal Pharmaceuticals' Accounts Payable of $228 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current Accounts Payable is $228 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.58, compared to a current price of $17.16 — trading 126.3% above its estimated fair value. The current Accounts Payable is $228 Mil. Amneal Pharmaceuticals' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current Accounts Payable is $228 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of $17.16 is trading 126.3% above its estimated GF Value™ of $7.58. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for AMRX:

  • Accounts Payable: $228 Mil
  • GF Value™: $7.58 vs. price of $17.16 (126.3% above fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Other Exchanges 2DT:Germany
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
63GF Score

Get the complete analysis for AMRX

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.16
Price
$7.58
GF Value